JonesResearch initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $46 price target Sionna is clinical stage biotech advancing novel cystic fibrosis drugs, the analyst tells investors in a research note. The firm says the company has developed two NBD1 stabilizers, SION-451 and SION-719, which, when in combination with complementary modulators, are likely superior to the standard of care, Vertex’s (VRTX) Trikafta.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
- Short Report: Frontier Group short positioning continues gaining altitude
- Sionna Therapeutics initiated with a Sector Perform at RBC Capital
- Sionna Therapeutics initiated with a Strong Buy at Raymond James
- Short Report: C3.AI short positioning at 2025-high